MHRT delivers similar therapeutic outcomes compared to CFRT in terms of tumour control and late toxicity for intermediate-risk PCa patients. Slightly more acute transient toxicity could be tolerated in favour of a shorter treatment course. UHRT should be regarded as an optional treatment for patients with low- and intermediate-risk disease applied at experienced centres in concordance with international and national guidelines.
Keyphrases
- radiation therapy
- prostate cancer
- oxidative stress
- clinical trial
- end stage renal disease
- newly diagnosed
- liver failure
- high resolution
- prognostic factors
- randomized controlled trial
- adipose tissue
- small cell lung cancer
- squamous cell carcinoma
- quality improvement
- metabolic syndrome
- type diabetes
- brain injury
- combination therapy
- radiation induced
- blood brain barrier
- peritoneal dialysis
- respiratory failure
- insulin resistance
- aortic dissection
- acute respiratory distress syndrome
- mass spectrometry
- oxide nanoparticles
- patient reported